Liver scan could cut lifelong drug burden for transplant patients
NCT ID NCT07206277
Summary
This study aims to see if a special ultrasound scan (FibroScan) can help doctors safely reduce the amount of anti-rejection drugs people need to take after a liver transplant. Participants who are at least 2 years post-transplant and stable will have their drug doses carefully lowered if their scan shows a low risk of rejection. The goal is to reduce the long-term side effects of these drugs, which can include kidney problems, diabetes, and heart disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.